Amylyx Pharmaceuticals, Inc. (AMLX)

Market Cap	324.29M
Revenue (ttm)	87.37M
Net Income (ttm)	-301.74M
Shares Out	88.60M
EPS (ttm)	-4.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	515,288
Open	3.800
Previous Close	3.870
Day's Range	3.555 - 3.835
52-Week Range	1.575 - 7.270
Beta	-0.51
Analysts	Buy
Price Target	7.50 (+104.92%)
Earnings Date	Mar 4, 2025

About AMLX

Amylyx Pharmaceuticals, Inc a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and tau...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 7, 2022
• Employees: 123
• Stock Exchange: NASDAQ
• Ticker Symbol: AMLX
• Website: https://amylyx.com

Analyst Forecast

According to 4 analysts, the average rating for AMLX stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 104.92% from the latest price.

Price Target

$7.5

(104.92% upside)

Analyst Consensus: Buy